Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock
November 04, 2014 at 13:32 PM EST
GlobeImmune IPO’d in June to little fanfare and has underperformed the biotech sector considerably since then. A key driving event in the next six months should put it back on the radar.
